Task B15: Synthesis of 35 g of an antiviral for pre-clinical in vivo and exploratory toxicology studies

任务 B15：合成 35 g 抗病毒药物，用于临床前体内和探索性毒理学研究

• 批准号: 10198174
• 负责人: JOHN MIRSALIS
• 金额: $ 7.06万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10198174
• 关键词: Adenoviruses; Antiviral Agents; Chemistry; Communicable Diseases; Cytomegalovirus; Development; Development Plans; Drug Kinetics; Evaluation; In Vitro; Interventional Agent Development; Lead; Microbiology; Poxviridae; Safety; Services; Smallpox; Support Contracts; Therapeutic; Toxicology; Toxin; in vivo; pathogen; pre-clinical; product development; programs; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

非临床传染病干预剂开发服务计划提供服务，促进针对传染病病原体和/或毒素的有前景的治疗药物的临床前产品开发。服务包括：临床前产品开发计划和评估；铅识别和开发；化学和GMP制造；体外和体内临床前微生物学、安全性、毒理学和药代动力学。